Chimigen Biosciences

Chimigen Biosciences is a clinical-stage biotechnology company focused on developing therapeutic vaccines and immunotherapies for chronic infectious diseases and oncology. The company's core technology is the proprietary Chimigen platform, which engineers chimeric proteins designed to deliver antigens directly to dendritic cells, the primary initiators of the immune response. This targeted approach aims to overcome immune tolerance and stimulate potent T-cell and B-cell responses. Chimigen's lead candidate, CMG-S01, is a therapeutic vaccine currently being evaluated for its potential to provide a functional cure for chronic Hepatitis B. The company maintains operations in both Beijing, China, and Worcester, Massachusetts, leveraging global expertise in vaccine development.